A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss

▶ CNBC Top News Jul 11, 2026 Jul 11 👁 3 views

📋 Article Summary

54 words

Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic. Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic. Read the full story on CNBC Top News via the link below.

ⓘ Summary only. Read the complete story on CNBC Top News below.

Full story on CNBC Top News

Read Full Article →

🔗 You will be taken to www.cnbc.com

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.